Islet Regeneration
Prompt the pancreas to regrow its own insulin-producing islets
The goal is to prompt the pancreas to regenerate its own islets — the clusters of insulin-producing cells — from within, restoring the body’s own insulin source rather than only supplying cells from outside.
Insulin is made in the islets of the pancreas. In diabetes these islets are lost or fail. The flagship capability — beta-cell regeneration — focuses on supplying new islet cells; this capability asks a complementary question: can the pancreas be coaxed to regrow its own islets in place? Restoring the body’s native insulin source would be the deepest possible repair.
We are building the capability to regenerate islets from the body’s own cells: stimulating the pancreas to make new beta cells, converting neighboring cells into insulin-producers, and protecting whatever islets form from the immune attack that destroyed the originals.
Regrowing islets from within
Converting neighboring cells Frontier
In research, other pancreatic cells (such as alpha cells) have been coaxed to become insulin-producing beta-like cells — turning the pancreas’s own cells into a new insulin source.
Stimulating beta-cell replication Frontier
Prompting surviving beta cells to multiply aims to rebuild islet mass from the body’s own cells.
Reprogramming in place Frontier
In-body reprogramming seeks to regenerate functioning islets directly within the pancreas.
Protecting new islets Frontier
Because the original loss is often autoimmune, regrown islets must be protected from renewed attack — shared with the immune-tolerance frontier.
Cited as evidence the capability is real — not as partners or endorsers.
Universities & institutes
Academic diabetes, islet-biology, and pancreatic-regeneration research centers studying beta-cell replication and cell conversion.
Government & programs
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, NIH) · NIH diabetes and regenerative-medicine programs.
Enabling science base
beta-cell replication · alpha-to-beta cell conversion · in-vivo reprogramming · islet biology · immune-tolerance research.
The technologies: cell-conversion approaches that turn other pancreatic cells into beta cells; beta-cell replication signals; in-vivo reprogramming; and immune-tolerance science to protect regenerated islets — building on the same biology advancing the beta-cell-regeneration flagship.
Alpha-to-beta conversion Frontier
Research has converted alpha cells into insulin-producing beta-like cells — proof the pancreas’s own cells can become a new insulin source.
Beta-cell replication Frontier
Approaches to stimulate surviving beta cells to multiply are advancing in the lab.
Built on islet-therapy progress Clinical (related)
The clinical success of lab-grown islet cells (the flagship) validates the broader goal of restoring islet function.
In-body reprogramming Frontier
Regenerating islets directly within the pancreas is an active frontier.
The honest challenges: regrowing the body’s own islets in people is frontier research, not a treatment — most evidence is from the lab and animals. New islets must be correctly regulated and, in type 1 diabetes, protected from the autoimmune attack that caused the loss. This capability is earlier than the lab-grown-islet flagship; we label it frontier and let the clinical progress lead.
The future, fully built
A pancreas that lost its insulin cells is prompted to regrow its own islets: new beta cells generated from the body’s own cells, islet mass rebuilt in place, the native insulin source restored and protected. The body’s own insulin factory becomes something we can help rebuild from within.
The proof, for this capability
Cited as evidence the capability is real, not as partners or endorsers.
Alpha-to-beta cell conversion
Research converted alpha cells into insulin-producing beta-like cells — the pancreas’s own cells as a new insulin source. Stage: Frontier (research).
Beta-cell replication
Approaches to stimulate surviving beta cells to multiply are advancing in the lab. Stage: Frontier.
Relation to islet-cell therapy
The clinical success of lab-grown islet cells (beta-cell regeneration flagship) validates restoring islet function. Stage: Clinical (related).
Honest framing
Real organizations and studies are cited as evidence the capability is real — not as partners or endorsers. Endogenous islet regrowth in people is frontier research, not a treatment; we do not claim otherwise.
Help build this future
Every signature grows the movement to make islet regeneration real — and free at the point of need.